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Abstract
The induction of cellular senescence by oncogenic signals acts
as a barrier to cellular transformation and is attained, in part,
by the elevation of the p16INK4a tumor suppressor gene. p16
expression is repressed epigenetically by Polycomb, but how
p16 is induced is not known. We report here that the p16 locus
is H3K4-methylated in highly expressing cells. H3K4 methyl-
transferase MLL1 directly binds to and is required, along with
its core component RbBP5, for the induction of p16 by
oncogenic Ras. We further show that damaged DNA binding
protein DDB1 and CUL4, which assemble distinct E3 ubiquitin
ligases by recruiting various WD40 proteins, act upstream of
MLL1-mediated H3K4 methylation. We showed that CUL4A
directly binds to p16 and that silencing DDB1 blocks Ras-
induced p16 activation. Ras expression dissociates BMI1 from
the p16 locus, whereas both CUL4 and MLL1 bind to the p16
locus similarly in both normal and oncogenic stimulated cells.
These results suggest that DDB1-CUL4 and MLL1 complexes
constitute a novel pathway that mediates p16 activation
during oncogenic checkpoint response and is repressed by
the polycomb repression complexes during normal growth of
young cells. [Cancer Res 2009;69(5):1809–14]
Introduction
p16INK4a encodes a specific inhibitor of the D-type cyclin-
dependent kinases (CDK) Cdk4 and Cdk6 (CDK4/6) and is
frequently mutated or inactivated in a wide range of human
cancers (1, 2). Mice deficient for p16 are more prone to
spontaneous cancers (3, 4) and have a reduced decline of stem
and progenitor cell function during aging (5–7). In contrast to its
well-established biochemical property as a CDK inhibitor and
physiologic function in tumor suppression and cell aging, little is
known about the molecular mechanism regulating the expression
level of p16. INK4 proteins (p16INK4a , p15INK4b , p18INK4c , and
p19INK4d) are relatively stable and the primary regulation of INK4 is
through transcriptional control.
The expression of individual INK4 genes is distinctly regulated
during development, in various adult tissues, and in response to
different cellular conditions (1, 2). The expression of p16 is
undetectable during embryogenesis and in young tissues (8, 9), due
in large part to the transcriptional repression by the collaborative
function of Polycomb repression complex (PRC) and RB family
proteins (10–14). The expression of p16 increases markedly with
aging in many tissues and contributes to an irreversible growth
arrest, termed replicative senescence, in both differentiated and
stem and progenitor cells during aging (5–7). Recently, hyper-
proliferative stimulation resulting from ectopic oncogene expres-
sion has been shown to cause similar cellular senescence, which
is accompanied by the induction of p16 (15, 16). The molecular
mechanism underlying oncogene-induced p16 activation is not
known and is investigated in this study.
Materials and Methods
Antibodies and immunologic procedures. Antibodies to BMI1 (F6;
Upstate), p16 (Ab-4; Neomarkers), MLL1 (BETHYL Laboratories, Inc.),
RbBP5 (BETHYL Laboratories, Inc.), WDR5 (ab22512; abcam), H-Ras (OP23;
Calbiochem), 3m-H3K4 (ab8580; abcam), 3m-H3K27 (Upstate), tubulin
(DM1A; Neomarkers), and actin (C-11; Santa Cruz) were purchased
commercially. Polyclonal antibodies to CUL4A (MADEAPRKGSF-
SALVGRTNG) and DDB1 (REKEFNKGPWKQENVE) were raised by immu-
nizing rabbits with synthetic peptides conjugated to keyhole limpet
hemocyanin. Rabbit polyclonal antibody to MLL1-C was kindly provided
by Dr. Y. Dou (University of Michigan, Ann Arbor, MI).
Cell culture, transfection, and retroviral transduction. The early
passage normal human diploid fetal lung fibroblast WI38 cells were
purchased from American Type Culture Collection. WI38 cells were cultured
in MEM supplemented with 10% fetal bovine serum (FBS), and 293T cells
was cultured in DMEM supplemented with 10% FBS. Cell transfection was
performed using calcium phosphate buffer. WI38 cells were infected with a
retrovirus expressing human papillomavirus oncoprotein E7 that binds
to and functionally inactivate Rb family proteins. Retroviruses encoding
shRNAs silencing MLL1, WDR5, RbBP5, Menin , and control GFP were
constructed by ligating respective oligonucleotides (MLL1 , GAAGTCA-
GAGTGCGAAGTC; WDR5 , CACCTGTGAAGCCAAACTA; RbBP5 , GAGCC-
GAGATGGTCATAAA; Menin , GTCGCAAGTGCAGATGAAG; GFP,
GCTACGTCCAGGAGCGCAC) into a pSuper-retro vector. pBabe H-RasG12V
was kindly provided by Channing Der (University of North Carolina at
Chapel Hill, Chapel Hill, NC). Retrovirus expressing shRNA silencing DDB1
has been described previously (17). The retroviral production and
transduction were performed as previous described (13).
Quantitative reverse transcription-PCR. Total RNA was extracted by
RNeasy (Qiagen), and 1 Ag was used for cDNA synthesis primed with
Oligo(dT)20 primers (Invitrogen). The cDNA was added to a quantitative
reverse transcription-PCR mixture that contained 1 SYBR Green PCR
master mix (Applied Biosystems) and 500 nmol/L gene-specific primers.
Assays were performed in triplicate on a 7900 HT sequence detection
system (Applied Biosystems). The PCR protocol comprised incubations at
50jC for 2 min and 95jC for 10 min, followed by 40 cycles, each consisting
of 95jC for 15 s and 60jC for 1 min. The expression level of each gene was
normalized with glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Specific PCR pairs used in this study have been described (13).
Chromatin immunoprecipitation assay. Chromatin immunoprecipi-
tation (ChIP) assays were performed as previous described (13). Briefly,
5  106 WI38 cells were treated with 1% formaldehyde for 10 min. The
cross-linking was stopped by the addition of 0.125 mol/L glycine and
incubated for 5 min. The cells were lysed with cell lysis buffer on ice
Requests for reprints: Yue Xiong, University of North Carolina, 22-012 Lineberger
Cancer Center, CB# 7295, Chapel Hill, NC 27599-7295. Phone: 919-962-2142; Fax: 919-
966-8799; E-mail: yxiong@email.unc.edu.
I2009 American Association for Cancer Research.
doi:10.1158/0008-5472.CAN-08-2739
www.aacrjournals.org 1809 Cancer Res 2009; 69: (5). March 1, 2009
Research Article
Research. 
on July 14, 2020. © 2009 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Published OnlineFirst February 10, 2009; DOI: 10.1158/0008-5472.CAN-08-2739 
[10 mmol/L Hepes (pH 7.9), 0.5% NP40, 1.5 mmol/L MgCl2, 10 mmol/L KCl,
0.5 mmol/L DTT and protease inhibitor cocktail]. After centrifugation at
4,000 rpm for 5 min, the cell pellets were lysed by sonication on ice with
nuclear lysis buffer [20 mmol/L Hepes (pH 7.9), 25% glycerol, 0.5% NP40,
0.42 mol/L NaCl, 1.5 mmol/L MgCl2, 0.2 mmol/L EDTA, and protease
inhibitor cocktail]. After centrifugation at 13,000 rpm for 10 min in a cold
room, the lysates were diluted with equal volume of dilution buffer [1%
Triton X-100, 2 mmol/L EDTA, 50 mmol/L NaCl, 20 mmol/L Tris-HCl
(pH7.9), and protease inhibitor cocktail]. Specific PCR pairs used in this
study have been described (13).
Results
Transcriptional activation of p16 is associated with H3K4
trimethylation. We (13) and others (14) recently found that the
p16 locus is histone H3 lysine27 (H3K27)-trimethylated and
repressed by Polycomb group (PcG) proteins. pRB proteins are
required for the recruitment of PcG proteins to p16 locus (13). We
found that associated with the decrease of PRC-mediated H3K27
methylation and activation of the p16 locus in WI38/E7 cells in
which pRB family proteins are functionally inactivated (Fig. 1A
and C), H3K4 trimethylation, a prevalent marker associated with
transcriptional activation, was increased broadly in the genome
(Fig. 1B) and specifically in the p16 locus (Fig. 1C and D). These
data indicate that the p16 locus is epigenetically regulated through
both repressive and active trimethylation at H3K27 and H3K4,
respectively.
MLL1 and RbBP5 are required for the p16 activation. The
findings that an increase of H3K4 trimethylation at the p16 locus is
associated with its transcriptional activation and that PcG and
Trithorax group (TrxG) proteins act in an opposing manner in the
regulation of Hox genes led us to test whether MLL1, a TrxG gene
encoding a SET domain H3K4 methyltransferase, is involved in p16
activation. We found that knocking down MLL1 in WI38 cells
substantially reduced both p16 protein and p16 mRNA (Fig. 2A).
The level of p18INK4c mRNA, but not two other INK4 genes
(p15INK4b , p19INK4d), were also decreased. This result is consistent
with previous findings that the p18 locus is bound and
transcriptionally activated by a MLL1 complex (18, 19) and also
indicates that INK4 genes are transcriptionally regulated different-
ly. ChIP assay showed that MLL1 directly binds to the p16 locus
(Fig. 2B). Notably, MLL1 binds to p16 not only in WI38/E7 cells
where BMI1 is dissociated from p16 , but also in WI38/mock cells
where p16 is bound and repressed by BMI1, indicating that BMI1-
mediated p16 repression is dominant over MLL1-mediated p16
activation and that BMI1 antagonizes MLL1 by a mechanism
independent of competition for the same binding site.
A common feature of several H3K4 methyltransferase complexes,
including MLL1, is the presence of a trimeric complex consisting of
three core components, RbBP5, Ash2L, and WDR5, which are
Figure 1. Transcriptional activation of p16
is associated with H3K4 trimethylation.
A, the levels of p16 mRNA were
determined in WI38/Mock and WI38/E7
cells by quantitative real-time reverse
transcriptase PCR (Q-RT-PCR). Data are
expressed relative to the corresponding
values for WI38/Mock cells; columns,
mean values were calculated from
triplicates of a representative experiment;
bars, SD. B, immunoblotting of H3K4
trimethylation levels of histones extracted
from WI38/Mock and WI38/E7 cells with
an antibody specific for trimethylated
H3K4. Total histone H3 was confirmed as a
loading control. C, a schematic
representation of the human p16 and
GAPDH gene loci and amplicons (a, b, c ,
and d ) used for ChIP assays. Antibodies
against trimethyl-H3K27, trimethyl-H3K4,
and IgG control were used in the ChIP
assay. PCR was carried out using primers
for each amplicon. D, abundance of
trimethyl-H3K4 on the p16 locus was
determined by Q-PCR following ChIP
using trimethyl-H3K4 antibody in WI38/
Mock and WI38/E7 cells.
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required for H3K4 methyltransferase activity (20, 21). Knocking
down RbBP5 reduced the level of p16 (Fig. 2C), further supporting
a direct function of MLL1 in p16 activation. Knocking down
WDR5 resulted in only a slight decrease of p16 , probably due to
incomplete silencing. Several groups reported that menin asso-
ciates with MLL1 and menin-dependent H3K4 methylation
maintains the expression of various genes, including multiple
HOX genes (22, 23) and CDK inhibitors p27 and p18 (18, 19). This
Figure 2. MLL1 and RbBP5 are required
for the p16 activation. A, WI38 cells
were infected with a retrovirus vector
encoding shRNA against either GFP or
MLL1 , selected by puromycin treatment for
3 d and harvested 8 d after initial infection.
The efficiency of MLL1 silencing and the
effect of MLL1 silencing on p27 and p16
protein expression were determined by
immunoblotting. The effects of MLL1
silencing on the expression of the four
INK4 and p27 genes were determined by
Q-RT-PCR. B, a schematic representation
of the human p16 and GAPDH gene loci
and amplicons (a, b , and c) used for ChIP
assays. Antibodies against BMI1, MLL1,
and IgG control were used in the ChIP
assay. PCR was carried out using primers
for each amplicon. C, WI38 cells were
infected with a retrovirus vector encoding
shRNA silencing individually GFP, MLL1,
WDR5 , or RbBP5 genes, selected by
puromycin treatment for 3 d and harvested
8 d after initial infection. The efficiency of
silencing each gene and the effect of
silencing on p16 expression were
determined by immunoblotting. D, WI38
and WI38/E7 cells were infected with a
retrovirus vector encoding shRNA against
either GFP or Menin, selected by
puromycin treatment for 3 d and harvested
8 d after initial infection. The efficiency
of silencing Menin and the effect of
silencing on p16 and p18 expression were
determined by immunoblotting.
Figure 3. CUL4A-DDB1 binds to and is required for p16 expression. A, WI38/E6 and WI38/E7 cells were infected with an empty retrovirus vector (Mock ) or retrovirus
vector encoding shRNA against DDB1 , selected by puromycin treatment for 3 and harvested 8 d after initial infection. The efficiency of DDB1 silencing and the
effect of DDB1 silencing on p16 expression were determined by immunoblotting. B, the effect of DDB1 silencing on the expression of p16 was determined by
Q-RT-PCR. C , a schematic representation of the human p16 and GAPDH gene loci and amplicons (a, b, c , and d) used for ChIP assays. Antibodies against Cul4A and
IgG control were used in the ChIP assay. PCR was carried out using primers for each amplicon.
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led us to test whether menin is involved in p16 activation.
Knocking down Menin decreased p18 expression, but not p16
expression (Fig. 2D), indicating that menin is not involved in p16
activation and that these two INK4 genes are regulated differently
by MLL. Supporting this, genome-wide analysis of Menin binding
revealed that Menin and MLL1 localize to the promoters of
thousands of human genes but do not always bind together (24),
suggesting the presence of multiple distinct MLL1 complexes.
CUL4A-DDB1 binds to and is required for p16 expression.
We (17) and others (25–27) recently discovered that DDB1, a 127
kDa protein initially identified as a component of the UV-damaged
DNA-binding protein, binds to several WD40 proteins containing
a DDB1 binding motif, including both RbBP5 and WDR5, and
bridges them to the CUL4-ROC1 catalytic core to assemble into
various distinct WD40-DDB1-CUL4-ROC1 E3 ubiquitin ligases.
Both RbBP5 and WDR5 are required for MLL1 H3K4 methyl-
transferase activity (20, 21). Moreover, silencing CUL4 or DDB1
causes a decrease of H3 methylation, especially H3K4 methylation
(25). These findings led us to test whether DDB1-CUL4 is involved
in p16 activation. We found that knocking down DDB1 reduced
p16 (and p18) not only in WI38/E7 cells, but also in WI38/E6 cells
where, although p53 is functionally inactivated, the RB family
proteins remain functional and PRC is effective in repressing
p16 (Fig. 3A and B). This result indicates that DDB1 is required
not only for the marked increase in expression seen in association
with RB pathway inactivation (as in WI38/E7 cells) but also the
more physiologic increase in p16INK4a expression that occurs
stochastically with serial passage of WI38 cells to induce their
senescence. ChIP assay showed that CUL4A binds to the p16 locus
(Fig. 3C). A direct binding of DDB1 to p16 promoter is yet to be
experimentally shown due to the lack of a DDB1 antibody capable
of precipitating DDB1. As in the case of MLL1-p16 binding, CUL4A
bound to the p16 locus in p16-repressed WI38/Mock nearly as well
as in p16-activated WI38/E7 cells, suggesting again that PRC-
mediated repression dominantly inhibits DDB1/CUL4A-mediated
activation of the p16 locus and that competing for the binding
site(s) in the p16 locus is not the major mechanism for either
PRC-mediated repression or CUL4-mediated activation.
Silencing DDB1 reduces H3K4 trimethylation of p16
promoter. To explore the functional relationship between DDB1,
MLL1, and polycomb complexes in the regulation p16 gene
expression, we first determined whether silencing DDB1 in WI38/
E7 cells would restore the binding of BMI1 p16 promoter. After
knocking down DDB1 (Fig. 4A), there was still no detectable
binding of BMI1 to p16 in WI38/E7 cells (Fig. 4B), indicating that
dissociation of BMI1 from p16 promoter is not due the competitive
occupancy by DDB1-CUL4A. This conclusion is consistent with the
notion that polycomb-mediated repression of p16 expression is
dominant over DDB1-meidated p16 activation.
We next determined whether the binding of CUL4A and MLL1 to
p16 promoter depends on each other by ChIP assay after silencing
either MLL1 or DDB1 in WI38/E7 cells. These experiments showed
that knocking down MLL1 (Fig. 4A), while nearly completely
abolished the binding of MLL1 to p16 promoter, had no
appreciable effect on the binding of CUL4A to p16 (Fig. 4C).
Likewise, silencing of DDB1 did not significantly affect the binding
of MLL1 to p16 . These results show that these two complexes bind
to p16 independently as oppose to one recruiting the other. We
note that silencing of DDB1 did not significantly affect the binding
of CUL4A to p16 promoter, suggesting that the binding of CUL4A
to p16 is not depending on DDB1. Finally, we determined H3K4
trimethylation in WI38/E7 cells after knocking down DDB1 and
found that knocking down DDB1 by shRNA resulted in a decrease
of H3K4 methylation of the p16 locus by >50% (Fig. 4D), suggesting
that DDB1-CUL4A facilitates, or may even be required for, MLL1-
mediated H3K4 methylation at the p16 locus.
CUL4-DDB1 and MLL1 are required for oncogene-induced
p16 expression. p16 gene expression is activated by a variety of
oncogenes, causing stable cell cycle arrest to protect cells from
Figure 4. Silencing DDB1 reduces H3K4 trimethylation of p16 promoter.
A, WI38/E7 cells were infected with retrovirus vectors encoding shRNA against
GFP, MLL1 , or DDB1, and selected by puromycin treatment for 3 d and
harvested 8 d after initial infection. Silencing of DDB1 or MLL1 was determined
by immunoblotting. B, antibodies against BMI1 and IgG control were used
in the ChIP assay to examine the binding of BMI1 to p16 promoter. PCR was
carried out using primers for each amplicon as indicated. C, antibodies against
MLL1, CUL4A, and IgG control were used in the ChIP assay. PCR was
carried out using primers for each amplicon as indicated in B. D, abundance of
trimethyl-H3K4 on the p16 locus was determined by Q-PCR following ChIP
using with trimethyl-H3K4 antibody in WI38/E7 cells with siRNA targeting either
GFP or DDB1. PCR was carried out using primers for each amplicon as
indicated in B .
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hyperproliferative stimulation (15). Transduction of oncogenic
H-RasG12V in WI38 cells resulted in a nearly 6-fold increase of p16
mRNA, whereas both p18 and ARF levels were decreased (Fig. 5A
and B). The latter is consistent with others’ findings that there is a
difference between human and murine cells in the regulation of
ARF in response to Ras-instigated oncogenic insults (28).
Oncogenic H-RasG12V also induced p16 in WI38/E6 cells (Fig. 4A),
indicating that induction of p16 by oncogenic H-RasG12V is not
dependent on the function of p53.
Knocking down MLL1 reduced oncogenic H-RasG12V–induced
p16 activation, whereas silencing DDB1 nearly completely abol-
ished p16 induction by oncogenic H-RasG12V (Fig. 5C). These
results identify two novel and critical components, DDB1 and
MLL1, on the pathway of oncogene-induced p16 activation. ChIP
assay showed that H-RasG12V expression completely disrupted the
binding of BMI1 to the p16 locus (Fig. 5D), although the steady-
state level of the BMI1 protein is slightly increased. The amounts of
MLL1 or CUL4A binding to the p16 locus, on the other hand, were
unchanged, again suggesting that PRC-mediated repression of
p16 acts dominantly over the DDB1-CUL4 and MLL1-mediated p16
activation and that removal of PRC-imposed repression is a
prerequisite for p16 induction.
Discussion
In this study, we identified two novel enzymatic activities, an E3
ubiquitin ligase mediated by the DDB1-CUL4-ROC1 complex and a
histone methyltransferase provided by the MLL1 catalytic complex
and a structural complex consisting of WDR5-RbBP5-Ash2L that
are required for p16 activation. We further show that a key
component from each enzyme complex, DDB1 and MLL1, are
required for oncogene-induced activation of p16 . The results
presented here provide the new insight into the epigenetic control
of p16 gene expression. These findings represent a significant
advance from and are mechanistically linked with previously
established epigenetic control of p16 repression by polycomb. Very
recently, Kia and colleagues (29) reported that in malignant
rhabdoid tumor (MRT)-derived cells that reactivation of p16
expression by the reintroduction of SWI/SNF chromatin-remodel-
ing complex is associated with the dissociation of PRC from and
recruitment of MLL1 to the p16 promoter. The results reported in
this study provide an additional support in the setting of primary
nontransformed cells that MLL1 binds to and is directly involved in
p16 activation. It is worthy noting that in these MRT cells, PRC can
be displaced by SWI/SNF, exhibiting a ‘‘recessive’’ feature to the
SWI/SNF complex. This is clear different form the dominant nature
of PRC over both MLL1 and CUL4-DDB1 as we have observed. It
will be important to determine whether this dominance of SWI/
SNF chromatin remodeling complex over PRC presents a special
case in MRT cells (30) and how SWI/SNF activity affect the
recruitment of both MLL1 histone methytransferase and CUL4-
DDB1 ubiquitin ligase complexes to the p16 promoter.
The detailed biochemical mechanisms underlying the function
of DDB1-CUL4A and MLL1 in p16 activation remain to be
determined, including in particular the identity of the substrate(s)
of DDB1-CUL4-ROC1 ubiquitin ligase and how the ubiquitina-
tion(s) affects MLL1-mediated H3K4 trimethylation. Ohtani and
colleagues (31) previously reported that ectopic expressed tran-
scription factors Ets1 and Ets2 also bind to and activate p16 in
senescent human fibroblasts and that Ras-induced p16 is
diminished by the ectopic expression of Id1, a dominant-negative
regulator of Ets factor. The functional relationship between Ets-Id
and DDB1-CUL4/MLL1 in mediating p16 activation remains to be
investigated. p38 mitogen-activated protein kinase (MAPK), a
Figure 5. CUL4-DDB1 and MLL1 are
required for oncogene-induced p16
expression. A and B, WI38 or WI38/E6
cells were infected with empty (Mock) or
oncogenic H-RasG12V–expressing
retroviruses and selected by puromycin
treatment. The levels of individual protein
(A) and mRNA (B) levels were determined
by immunoblotting and Q-RT-PCR,
respectively. C, WI38 cells were infected
with the retroviruses expressing empty
(Mock ) or H-RasG12V and shRNA targeting
GFP, MLL1 , or DDB1, selected by
puromycin treatment for 3 d and harvested
8 d after initial infection. The levels of
individual protein were determined by
immunoblotting. D, a schematic
representation of the human p16 and
GAPDH gene loci and amplicons (a, b, c ,
and d) used for ChIP assays. Antibodies
against BMI1, MLL1, CUL4A, and IgG
control were used in the ChIP assay. PCR
was carried out using primers for each
amplicon as indicated. The BMI1 protein
level was determined by immunoblotting.
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major cellular stress checkpoint mediator, has also been previously
implicated in p16 induction by Ras oncogene (32, 33). Whether
activation of p38 MAPK leads to derepression of p16 , through
either induction of cyclin D and thus inactivation of RB or
phosphorylation of BMI1 and thus dissociation of polycomb from
chromatin (34), is also an interesting issue that is yet to be
investigated.
A significant issue concerns whether the well-established DNA
damage checkpoint pathway, which is mediated by ATM/ATR,
CHK1/CHK2, and p53 and was recently shown to be required for
oncogene-induced senescence (35–38), is linked with the DDB1-
CUL4-MLL1 in oncogene-induced p16 activation. It has long been
noticed that inactivation of p53 does not affect p16 induction
(reviewed in ref. 1). Our data showed that inactivation of p53 has
no detectable effect on Ras-induced p16 expression (Fig. 5A). These
observations, together with the dissociated kinetics between p53
activation (as early as within 24 hours) and p16 induction by either
DNA damage or by oncogenic Ras (more than a week), argue
against the possibility that Ras signals a component of either
DDB1-CUL4-ROC1 ligase or MLL1 methyltransferase in a p53-
dependent manner. Our extensive efforts have thus far failed to
detect any significant effect of ATM, ATR, CHK1, or CHK2 in Ras-
mediated p16 activation, raising the possibility that DDB1-CUL4,
WDR5-RbBP5-Ash2L, and MLL1 complexes constitute a novel
pathway that mediates p16 activation during oncogenic checkpoint
response and cell aging and that is repressed during normal growth
of young cells by the PRCs.
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